Knoa Pharma

Knoa Pharma is a specialty pharmaceutical company dedicated to improving the lives of patients with central nervous system (CNS) disorders. The company focuses on developing optimized formulations of established medications to address unmet clinical needs, particularly in the pediatric and adult ADHD markets. Its lead program, KNP-101, is a proprietary long-acting liquid formulation of dexmethylphenidate designed to provide a more consistent therapeutic effect and easier administration. Knoa Pharma leverages its expertise in drug delivery and clinical development to advance a pipeline of CNS-focused therapies. The company is led by a management team with significant experience in the successful development and commercialization of CNS products, including the founders of Collegium Pharmaceutical and BioDelivery Sciences.